Seeking Alpha

Sell-side weighs in as Chelsea Therapeutics soars

  • The sell-side continues to weigh in on Chelsea Therapeutics (CHTP +125.2%) following Thursday's Northera panel.
  • Deutsche's Robyn Karnauskas lifts her target to $5 from $4, but notes the FDA could still decide against approval. Fair value is $8-9 assuming approval.
  • Meanwhile, Wedbush is out reiterating an Outperform rating and an $8 target. "Our impression was that the panel came to appreciate the vagaries of clinical trials for neurological disorders—especially in orphan diseases like NOH," analyst Liana Moussatos says.
Comments (2)
  • Michael Vascocu
    , contributor
    Comments (381) | Send Message
     
    With such an overwhelmingly positive panel vote with only one 'no' it would be ridiculous to think that the FDA would say no a second time ~ if so, lawsuit maybe?
    15 Jan 2014, 09:50 AM Reply Like
  • hneumann
    , contributor
    Comments (619) | Send Message
     
    Ridiculous yes, but yesterday was a big surprise. Who is to be trusted nowadays ? To put it even more ridiculous: maybe some panel members bought the stock for $ 2.50. Makes one remind on match-fixing in sportsgames.
    15 Jan 2014, 02:24 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs